- Home
- FEBO vs NLSP Comparison
FEBO vs NLSP Comparison
Compare FEBO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- NLSP
- Stock Information
- Founded
- FEBO 1993
- NLSP 2015
- Country
- FEBO Hong Kong
- NLSP Switzerland
- Employees
- FEBO N/A
- NLSP N/A
- Industry
- FEBO
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- NLSP Health Care
- Exchange
- FEBO Nasdaq
- NLSP Nasdaq
- Market Cap
- FEBO 12.6M
- NLSP 12.4M
- IPO Year
- FEBO 2023
- NLSP 2021
- Fundamental
- Price
- FEBO $1.09
- NLSP $2.86
- Analyst Decision
- FEBO
- NLSP
- Analyst Count
- FEBO 0
- NLSP 0
- Target Price
- FEBO N/A
- NLSP N/A
- AVG Volume (30 Days)
- FEBO 8.7K
- NLSP 385.9K
- Earning Date
- FEBO 07-15-2025
- NLSP 07-07-2025
- Dividend Yield
- FEBO N/A
- NLSP N/A
- EPS Growth
- FEBO N/A
- NLSP N/A
- EPS
- FEBO N/A
- NLSP N/A
- Revenue
- FEBO $17,110,653.00
- NLSP N/A
- Revenue This Year
- FEBO N/A
- NLSP N/A
- Revenue Next Year
- FEBO N/A
- NLSP N/A
- P/E Ratio
- FEBO N/A
- NLSP N/A
- Revenue Growth
- FEBO 11.58
- NLSP N/A
- 52 Week Low
- FEBO $0.93
- NLSP $1.30
- 52 Week High
- FEBO $17.68
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- FEBO 40.32
- NLSP 68.80
- Support Level
- FEBO $1.01
- NLSP $2.51
- Resistance Level
- FEBO $1.26
- NLSP $3.08
- Average True Range (ATR)
- FEBO 0.07
- NLSP 0.21
- MACD
- FEBO -0.00
- NLSP 0.04
- Stochastic Oscillator
- FEBO 2.00
- NLSP 75.17
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.